Lurbinectedin plus atezolizumab significantly reduced the risk of disease progression or death by 46% compared with atezolizumab alone.

Atezolizumab is already approved for use in non–small cell lung cancer (NSCLC) as well as bladder cancer and was recently approved for use in triple-negative breast cancer.

During a live event, Bruna Pellini, MD, discussed IO monotherapy as a first-line option for non–small cell lung cancer with ...

Jazz Pharmaceuticals Announces Zepzelca® (lurbinectedin) and Atezolizumab ... "In the U.S., approximately 30,000 new cases of small cell lung cancer are diagnosed each year, ...

Researchers are specifically studying the drug atezolizumab for non-small cell lung cancer. "It can now be given as a subcutaneous injection under the skin, which is a heck of a lot easier for people.

Application based on data from IMforte, the first Phase 3 trial demonstrating statistically significant and clinically meaningful improvements in both progression-free and overall survival in the ...

HealthDay News — Maintenance therapy with lurbinectedin (lurbi) and atezolizumab (atezo) helps some patients with extensive-stage small cell lung cancer (ES-SCLC) live longer versus maintenance ...

This is not the first trial to show a lack of benefit when adding immunotherapy to SBRT in patients with early-stage, inoperable NSCLC.

Atezolizumab With Platinum and Etoposide Chemotherapy Followed by Cystectomy for Patients With Localized Small Cell Neuroendocrine Bladder Cancer – An ASCO Reading Room selection November 30, 2023 ...

In the U.S., approximately 13 percent of lung cancers are small cell. 2 Approximately 30,000 new cases of small cell lung cancer (SCLC) are reported in the U.S. each year. 2, 3 The risk for ...

Application based on data from IMforte, the first Phase 3 trial demonstrating statistically significant and clinically meaningful improvements in both progression-free and overall survival in the ...